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cover a new health technology is best accomplished using a model
that mathematically combines inputs from various sources, together
with assumptions about how these ﬁt together and what might
happen in reality. This need to make assumptions, the complexity
of the resulting framework, the technical knowledge required, as well
as funding by interested parties have led many decision makers to
distrust the results of models. To assist stakeholders reviewing a
model’s report, questions pertaining to the credibility of a model were
developed. Because credibility is insufﬁcient, questions regarding
relevance of the model results were also created. The questions
are formulated such that they are readily answered and they aresee front matter Copyright & 2014, International S
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responses indicate strongly that a model should not be used for
decision making: these trigger a “fatal ﬂaw” indicator. It is hoped that
the use of this questionnaire, along with the three others in the series,
will help disseminate what to look for in comparative effectiveness
evidence, improve practices by researchers supplying these data, and
ultimately facilitate their use by health care decision makers.
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Four Good Practices task forces developed a consensus-based set
of questionnaires to help decision makers evaluate 1) prospective
and 2) retrospective observational studies, 3) network meta-
analysis (indirect treatment comparison), and 4) decision analytic
modeling studies with greater uniformity and transparency [1,2].
The primary audiences for these questionnaires are assessors of
research studies for health technology assessment, formulary
placement, and health care services decisions. They are intended
for use without requiring deep levels of knowledge and expertise.
This report focuses on the questionnaire to assess the relevance
and credibility of modeling.
Decision analytic models consist of equations that are used to
estimate the results of a decision, such as health outcomes and
costs, for speciﬁed scenarios involving particular interventions inspeciﬁed populations [3]. They can help decision makers anticipate
the outcomes they can expect if they implement the interventions
in their settings [4]. Mathematical models can be very useful when
there are no empirical studies that adequately address the decision
maker’s problem, and when it is not feasible to conduct such
studies within the time limit of the decision [5,6]. In such cases, a
model may be the only tool available to give decision makers the
information they need for an informed decision [7,8].
Like any other source of information, mathematical models
have limitations that decision makers should understand before
they use the models’ results [9]. All models involve assumptions
about the clinical condition and its course, possible interventions
and their effects, the behavior of people involved (patients, clini-
cians, caregivers, etc.), and other determinants of what may
happen [10]. Some of these assumptions are encoded mathe-
matically in equations that relate the change in one parameterociety for Pharmacoeconomics and Outcomes Research (ISPOR).
clude modeling activities among their professional practices and
esults. Some members of the Task Force own intellectual property
ted by citations to articles authored by Task Force members. The
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Background to the Task Force
On May 21, 2011, the Board of Directors approved, in principle,
ISPOR’s participation with the Academy of Managed Care
Pharmacy (AMCP) and the National Pharmaceutical Council
(NPC) in the Comparative Effectiveness Research Collaborative
Initiative (CER-CI) for advancing appropriate use of outcomes
research evidence to improve patient health outcomes. ISPOR’s
contribution to the CER-CI was to develop articles on how to
assess prospective and retrospective observational studies,
indirect treatment comparison (network meta-analysis), and
decision analytic modeling studies to inform health care
decision making. Four Good Practice task forces were created
to develop these articles. Task Force Chairs were identified from
leaders of ISPOR Good Research Practices task forces. Each Task
Force consisted of two members from the AMCP, the NPC, and
the ISPOR.
Each Task Force met independently via teleconference. In
addition, the Task Force Chairs met via teleconferences and
face-to-face meetings held on April 20, 2012 (San Francisco,
CA, USA), June 3, 2012 (Washington, DC, USA), June 28-29,
2012 (Boston, MA, USA), November 4, 2012 (Berlin, Germany),
and May 21, 2013 (New Orleans, LA, USA), to coordinate a
common outline and format for these articles. A focus group
representing the US formulary decision-making community
(22 participants) was convened April 20, 2012, at the AMCP
Meeting, San Francisco, CA, USA, for feedback on the draft
outline, format, and content of the assessment articles. The
content of these reports was presented for comment at the
ISPOR Annual International Meetings held June 4, 2012, and
May 22, 2013, and the European Congress held November 5
and 6, 2012.
Draft modeling studies Task Force reports were sent for
comment to their respective review group. Comments for
each group were considered, and final draft reports were
sent to the ISPOR membership for comment on September
23, 2013. Overall, there were 48 written comments for the
modeling Task Force. All written comments are published
on the ISPOR Web site, which can be accessed via the
Research menu on ISPOR’s home page: http://www.ispor.
org. The final report was submitted to Value in Health.
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The model is implemented in software used to compute the
expected results given the particular inputs and assumptions
made [12].
In using a modeling study, decision makers must determine
how much conﬁdence to place in the results [13]. Some may not
have sufﬁcient technical proﬁciency to fully understand the work-
ings of the model, the equations that power it, or even the way data
were analyzed to supply the inputs [14,15]. Moreover, there is
always uncertainty about the results of a modeling analysis because
the inputs are often derived from analyses of other data (“param-
eter” uncertainty) [16] and because of the assumptions made in
constructing the model, including about the system at issue [17].
Thus, decision makers need to know the extent to which they
should trust the results of the model [18,19]. Is it sufﬁciently
relevant and credible to inform the decision at hand?
Few tools have been developed to aid in the assessment of
decision analytic models [20,21], and most of these are aimed at
technically adept users [22]. Moreover, new guidelines concerning
the development of models have recently been issued
[3,10,15,16,23–25]. Thus, it is timely to provide a questionnaire
to help users assess the extent to which the model follows good
practices and whether it can help themmake an informed choice.Questionnaire Development
One issue in creating questionnaires for decision makers is
whether they should be linked to a scorecard. Concerns were
raised by the task forces that a scorecard with an accompanying
scoring system may be misleading; it would not have adequate
validity and measurement properties. Scoring systems may also
provide users with a false sense of precision and have been shown
to be problematic in the interpretation of randomized trials [26].
An alternative to a scorecard is a checklist. It was felt by the
Task Force that checklists might also mislead users in their
assessments because a study may satisfy all the elements of a
checklist and still harbor “fatal ﬂaws” in the methods applied in
the publication. Moreover, users might have the tendency to
count up the number of elements present converting it into an
implicit score, and then apply that implicit scoring to their overall
assessment of the evidence. In addition, the applicability of a
study may depend on whether there is any other evidence that
addresses the speciﬁc issue or the decision being made. In
general, an evidence evaluator needs to be aware of the strengthsand weaknesses of each piece of evidence and apply his or her
own reasoning. Indeed, it was felt that in addition to the potential
for implicit or explicit scoring to be misleading, it would under-
mine the educational goal that the questionnaires provide.Questionnaire Items
When evaluating a modeling study, two main questions should
be considered. First, how closely does the problem analyzed by
the modelers apply to the problem faced by the decision maker
(“relevance”)? Second, how credible is the modeling?
Every analysis is conducted for a speciﬁc population, inter-
ventions, comparison, outcomes, and time horizon (the “model
setting”). For the modeling results to accurately predict the
outcomes that will occur in the “decision setting,” two conditions
must be met. First, the two settings should be as similar as
possible. Any discrepancies between the two will affect how well
the model predicts what will occur in the decision setting.
Second, the model should be as credible as possible in predicting
the outcomes in the model setting.
Accordingly, the modeling assessment questionnaire is divided
into two sections. The ﬁrst section helps assess the “relevance” of
the model in the decision setting; the second helps determine the
“credibility.” Each section consists of a number of “main questions”
that cover the principal topics (Table 1). To assist users in
responding to these main questions, optional “helper questions”
have been provided as well. Possible responses to each question
are “Yes,” “No,” or “Can’t Answer.” If the user selects “Can’t
Answer,” four additional responses are available: “Not Applicable,”
“Not Reported,” “Not Enough Information,” or “Not Enough Train-
ing.” Because there will inevitably be degrees of sufﬁciency, users
may also want to keep appropriate notes (e.g., “spot on” vs. “similar
enough to consider the results, though they can’t be applied
literally”). A space for notes is provided for every question and
the overall assessments. After responding to individual questions
within each section, the user will determine whether the modeling
study provides information that is “sufﬁciently” or “insufﬁciently”
relevant and credible to consider in making the decision at hand.
Relevance
Relevance addresses the extent to which the results of the model
apply to the setting of interest to the decision maker. Stated
another way, relevance asks how closely the model setting
Table 1 – Questionnaire to assess the relevance and credibility of a modeling study.
S. no. Question Helper questions to consider
Relevance
1 Is the population relevant? Are the demographics similar?
Are risk factors similar?
Are behaviors similar?
Is the medical condition similar?
Are comorbidities similar?
2 Are any critical interventions missing? Does the intervention analyzed in the model match the
intervention you are interested in?
Have all relevant comparators been considered?
Does the background care in the model match yours?
3 Are any relevant outcomes missing? Are the health outcomes relevant to you considered?
Are the economic end points relevant to you considered?
4 Is the context (settings and circumstances) applicable? Is the geographic location similar?
Is the health care system similar?
Is the time horizon applicable to your decision?
Is the analytic perspective appropriate to your decision
problem?
Credibility
Validation
1 Is external validation of the model sufﬁcient to make
its results credible for your decision?
Has the model been shown to accurately reproduce what was
observed in the data used to create the model?
Has the model been shown to accurately estimate what
actually happened in one or more separate studies?
Has the model been shown to accurately forecast what
eventually happens in reality?
2 Is internal veriﬁcation of the model sufﬁcient to make
its results credible for your decision?
Have the process of internal veriﬁcation and its results been
documented in detail?
Has the testing been performed systematically?
Does the testing indicate that all the equations are consistent
with their data sources?
Does the testing indicate that the coding has been correctly
implemented?
3 Does the model have sufﬁcient face validity to make its
results credible for your decision?
Does the model contain all the aspects considered relevant to
the decision?
Are all the relevant aspects represented and linked according
to the best understanding of their characteristics?
Have the best available data sources been used to inform the
various aspects?
Is the time horizon sufﬁciently long to account for all relevant
aspects of the decision problem?
Are the results plausible?
If others have rated the face validity, did they have a stake in
the results?
Design
4 Is the design of the model adequate for your decision
problem?
Was there a clear, written statement of the decision problem,
modeling objective, and scope of the model?
Was there a formal process for developing the model design
(e.g. inﬂuence diagram, concept map)?
Is the model concept and structure consistent with, and
adequate to address, the decision problem/objective and the
policy context?
Have any assumptions implied by the design of the model been
described, and are they reasonable for your decision
problem?
Is the choice of model type appropriate?
Were key uncertainties in model structure identiﬁed and their
implications discussed?
Data
5 Are the data used in populating the model suitable for
your decision problem?
All things considered, do you agree with the values used for the
inputs?
Did the approaches to obtaining and processing the data inputs
meet the criteria from their corresponding questionnaires?
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Table 1 – continued
S. no. Question Helper questions to consider
Analysis
6 Were the analyses performed using the model
adequate to inform your decision problem?
7 Was there an adequate assessment of the effects of
uncertainty?
Reporting
8 Was the reporting of the model adequate to inform
your decision problem?
Did the report of the analyses provide the results needed for
your decision problem?
Was adequate nontechnical documentation freely accessible to
any interested reader?
Was technical documentation, in sufﬁcient detail to allow
(potentially) for replication, made available openly or under
agreements that protect intellectual property?
Interpretation
9 Was the interpretation of results fair and balanced?
Conﬂict of
Interest
10 Were there any potential conﬂicts of interest?
11 If there were potential conﬂicts of interest, were steps
taken to address these?
Note. Relevance questions relate to the usefulness of the modeling study to inform the particular health care decision at issue. Based on
responses to the individual questions, the overall relevance of the modeling study for that decision is assessed as Sufﬁcient or Insufﬁcient.
If the modeling study is considered sufﬁciently relevant, its credibility is assessed. The credibility is captured with questions in the following
seven domains, Validation, Design, Data, Analysis, Reporting, Interpretation, and Conﬂict of interest. Based on responses to the individual questions,
each domain is assessed as a Strength, Neutral, Weakness, or Fatal ﬂaw. If a response triggers a “fatal ﬂaw” indicator, the domain is marked as a
fatal ﬂaw, indicating that the modeling study has serious credibility issues. Based on the domain assessments, the overall credibility of the
modeling study is judged as Sufﬁcient or Insufﬁcient.
 The questionnaire consists of 15 questions related to the relevance and credibility of a modeling study. Each question is answered with
Yes/No/Can’t Answer.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 7 4 – 1 8 2 177matches the decision setting [27]. There is no single rating for
relevance. Because each decision maker is interested in a differ-
ent setting, the relevance of the model analyses may vary for
each setting. Relevance has to be determined by each decision
maker, and the relevance conclusion determined by one will not
necessarily apply to other decision makers. At the end of the
Relevance section, the user determines whether the relevance of
the study is “Sufﬁcient” or “Insufﬁcient” to use in making a
decision.1. Is the population relevant?
Does the population modeled sufﬁciently match the decision
maker’s population? Population characteristics to consider
include demographic characteristics such as age and sex, nation-
ality, race/ethnicity; risk factors such as average blood pressure,
cholesterol, and body mass index levels; behaviors such as smok-
ing and adherence to treatment; details of the condition, such as
stage and severity and past and current treatments; and comor-
bidities. These aspects are covered in ﬁve helper questions.2. Are any critical interventions missing?
Do the modeled interventions match those of interest to the decision
maker? Were all relevant comparators considered; How well does
background care in the model match the modes of care in the
decision setting? Intervention characteristics to consider include
the following: technology used; administration technique; dose;
duration of treatment (or protection for a vaccine); mode of
administration; skill level and behavior of provider; posttreat-
ment monitoring and care; and duration of follow-up. These
aspects are covered in three helper questions.3. Are any relevant outcomes missing?
Are the clinical and patient-centered health outcomes assessed in
the study meaningful to the decision maker? Have all relevant
economic end points been addressed? Outcomes that matter to
patients or health care systems are increasingly emphasized
instead of surrogate end points (e.g., cholesterol levels). These
aspects are addressed in two helper questions.4. Is the context (settings and circumstances) applicable?
Is the context of the study applicable to the decision setting?
Factors to consider are the study time horizon; characteristics of
the health care system, including the cost structure; analytic perspec-
tive; and practices related to the geographic location. These are
covered in ﬁve helper questions.
The time horizon refers to the period of time for which the
simulation is run. Typically, this is deﬁned in terms of the
patients simulated rather than calendar time (e.g., everyone
was simulated until death—a lifetime horizon). The time horizon
should match the time horizon of interest to decision makers,
but, ideally, should not be so short that important outcomes
cannot manifest.
The perspective is the point of view taken in the analysis.
Although a strict economic principle holds that all analyses
should be from the so-called societal perspective (include all
economic consequences across the community), nearly all anal-
yses focus on factors relevant to stakeholders. For example, from
a health care plan’s perspective, the cost of care and expected
patient outcomes are considered but other economic consequen-
ces such as worker productivity, absenteeism, or presenteeism
may not be taken into account. A narrower perspective should be
Fig. 1 – Modeling study assessment questionnaire ﬂowchart. The cross-out mark indicates a fatal ﬂaw and the thumbs down
an unfavorable response. Of note, all questions provide a “can’t answer” option that is not reﬂected in the diagram. Thus,
insufﬁcient information does not necessarily trigger an unfavorable response or fatal ﬂaw.
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relevant it is in the decision setting.
Credibility
The credibility of a modeling analysis should be assessed at
several levels: validation, design, data, analyses, reporting,
interpretation, and conﬂicts of interest. Validation assesses
how well the model accords with reality. The design should
follow accepted standards for conceptualizing and framing the
model. The data used in building the model should be suitable
for the purpose, properly analyzed, and incorporated in the
model. Analyses should provide the information required to
support the decision maker. Although not speciﬁcally pertaining
to a model’s credibility, its reports should be sufﬁcient to assess
relevance and credibility. To evaluate the degree to which
credibility has been properly assessed (and what the level of
accuracy is), adequate documentation of the model and of the
validity assessments must be provided. Although users are free
to reach their own conclusions, it is helpful if interpretations are
balanced and consistent with the results, keeping in mind the
limitations of the model and data. Finally, any potential con-
ﬂicts of interest that might have affected the modeling study
and what the researchers have done about them should be
described.
The ﬂow of questions in this section is shown in Figure 1.
Validation
Validation is a process for judging a model’s accuracy in making
relevant predictions [15]. That information can be used by
decision makers to determine to what extent they should trust
the results. While transparency can help users understand what
a model does and how it does it, validation is the only way for
readers to determine how well it does it. It is very difﬁcult for
anyone other than the modelers to assess validity fully. Because
models use mathematical structures to make their predictions,
directly making the validity assessments requires technical
expertise and full access to the model and external data. A more
feasible task for users of models is to evaluate the extent to
which the modelers have assessed validity (bearing in mind that
validity pertains to a particular application of the model—it is nota property of the model per se, and the degree of validity required
depends on the question posed). It should be noted that peer
review, as currently practiced, is insufﬁcient to determine that a
model’s results are fully validated. Just because a modeling
analysis has been published does not mean that it is credible—
much depends on the quality of the peer review process. If a
model has not been sufﬁciently validated, or the decision maker
cannot tell this information, then the results of the model should
not be trusted (i.e., this is a fatal ﬂaw).
Points to think about in general: Did the model builders have a formal process for validating
their model? [10] Has a report of the validation been made available?
 Is the validation process well described?
 Have the types of validations performed been detailed?
 Were the approaches to ﬁnding data sources for the validation
reasonably comprehensive?
 Were the data sources used for validation appropriate for the
proposed uses of the model?
 Were the methods for setting up the simulation of each
source adequately described? Do they seem reasonable? For
example, how well was the simulated population matched to
the validation one? Were those performing the validations blind to the results of
the model? Were results of the validations provided in sufﬁcient detail?
 Were the implications of the validations discussed adequately?
 Were there quantitative measures of how well the model’s
results match the outcomes observed in the data source?
There are three main categories: external validity, internal
veriﬁcation, and face validity. The questionnaire includes one
main question and several helper questions for each of these.
External Validation
1. Is external validation of the model sufﬁcient to make its
results credible for your decision?
In external validation, a model is used to simulate a real data
source, such as a clinical trial, and the calculated outcomes are
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be applied to the model as a whole, or to parts of the model that
address such things as creation of simulated populations, disease
incidence (including effects of patient characteristics, risk factors,
and behaviors), disease progression, care processes and behav-
iors, occurrence of clinical outcomes, and effects of interventions.
External validation is essential in establishing the credibility of
the model, and a “No” answer to this question should be
considered a fatal ﬂaw. Helper questions address types of
external validation. There are three main types: dependent
(including partially dependent), independent, and predictive.
When reviewing external validations, important questions to
ask include such things as how many were performed; were
landmark epidemiological studies and clinical trials included;
were all relevant arms of a trial included; were all relevant
outcomes included; and was there an attempt to “cherry pick”
the studies, treatment arms, or outcomes. It is important that the
sources used for validation provide a good check of the model’s
credibility. For example, although it may appear impressive that
a model reproduces each one of the data sources used to build it,
this only reﬂects that the data sources were correctly imple-
mented. It does not assure you that the model can accurately
estimate results beyond that.
Dependent validation. This type of validation involves simulating
a data source that was used to build the model or parts of the
model that are being validated [29]. It is considered “dependent”
because the same source is used to both estimate and validate the
model’s equations. For example, a model might use data from a
clinical trial to estimate disease progression. The modelers would
simulate the same trial to conﬁrm that their results are in accord.
Every model should, at a minimum, be able to reproduce the data
sources that were used to create it. Models validated only by
dependent validations are not as credible as those validated by
independent or predictive validations but can still be useful.
In partially dependent validations, the model is used to
simulate a data source used for one component (the dependent
part), but this simulation covers other components as well (the
“independent” part) [30]. For example, a clinical trial might be
used to estimate a single equation for mortality but other
simulation components are derived from other sources. If simu-
lating this trial yields results that are in accord, then a fairly
strong partially dependent validation has been attained.
Independent validation. In an independent validation, the model
is used to simulate a study that was not used in any way to build
the model [31]. Ideally, the independent sources are chosen by an
independent panel on the basis of the intended use of the model,
not on convenience or likelihood of a successful validation. Data
sources for independent validations should be identiﬁed through a
formal search to involve settings, populations, interventions, and
outcomes similar to those in the decision setting. They should also
have strong designs (e.g., large size, representative population,
formal protocol, and detailed reporting) and be as recent as possible.
Predictive validation. Predictive validations involve identifying a
data source, such as a clinical trial, that has not yet been
completed, and predicting the results before they are known
[32]. This type of validation is very convincing because it elimi-
nates any opportunity for the modelers to be affected by the
results. Opportunities for this type of validation are relatively rare
because there may not be any suitable studies in progress or the
model’s results are needed before the studies will be completed.
While predictive validation enhances the credibility of a model,
absence of predictive validation should not negatively affect its
credibility.Veriﬁcation
2. Is internal veriﬁcation of the model sufﬁcient to make its
results credible for your decision?
Veriﬁcation (also called internal validity, internal consistency, or
technical validation) examines the extent to which the mathe-
matical calculations are performed correctly in the model and are
consistent with the model’s speciﬁcations [29]. The methods will
depend on the model’s complexity. There are two main steps:
verifying the individual equations, and verifying their implemen-
tation in code. Equations and parameters should be validated
against their sources. Veriﬁcation [15] helps to ensure that there
are no unintentional computational errors, but it does not
evaluate the accuracy of the model’s structure or predictions.
Parameters for the equations might be ﬁtted using good data
sources and technique, and the equations might be accurately
coded, but the resulting model might still be inaccurate if the
structure is poorly chosen. Helper questions address the follow-
ing: Has the process of internal veriﬁcation and its results been
documented? Has the testing been performed systematically?
Does the testing indicate that the equations are consistent with
their data sources? Does the testing indicate that the coding has
been correctly implemented?
Face Validity
3. Does the model have sufﬁcient face validity to make its
results credible for your decision?
Face validity of the model addresses how plausibly the model
represents the diseases, settings, populations, interventions, and
outcomes it is intended to analyze [33]. This is the easiest aspect
of credibility for a user to check because it does not require in-
depth technical knowhow. Helper questions address whether the
model contains all the aspects of the population, diseases,
interventions, outcomes, and setting appropriate to its intended
use; all the aspects are represented and linked according to
current knowledge; assumptions made about the occurrence
and progression of diseases are sufﬁciently realistic for the
intended uses; the best available data sources were used; the
time horizon was sufﬁciently long to account for all relevant
aspects of the decision problem; and the results were plausible or
explainable. If others rated the face validity, did they have a stake
in the results that might bias their conclusions?
If parts of the model fail face validity, the effect on credibility
depends on the user’s judgment about whether the questionable
parts are so unrealistic or inappropriate that they affect the
accuracy of the results. For example, a state-transition model
might assume that everyone with, say, osteoporosis will respond
equally to treatment, no matter how long they have had the
condition, how many previous fractures they have had, their
bone mineral density, and so forth. If that model is to be used
to evaluate osteoporosis treatment, those assumptions would
have a strong negative effect on face validity. If the only purpose
of the model is to estimate the age-speciﬁc incidence of osteopo-
rosis, however, then assumptions about treatment, no matter
how inaccurate they may be, will not materially affect the results.
It should be noted that the model may contain additional
aspects beyond the ones relevant to the problem at hand. Users
may evaluate the face validity of only those parts of the model
that are pertinent to their decision problem.
Design
4. Is the design of the model adequate for your decision
problem?
The design of the model refers to the aspects of the decision
problem that are included, the relationships between them, and
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“Aspects” is used very broadly to include such things as physio-
logical parameters, treatments, cure processes, behaviors, health
outcomes, costs, environmental factors, and so forth. The math-
ematical structure determines how these aspects and their
relationships are represented mathematically. The structure
strongly affects such things as whether the model is continuous
in time [34], whether variables that are continuous in reality are
represented as such in the model [35] (e.g., is blood pressure
measured continuously or is it represented through categories
such as “normal,” mild hypertension,” etc.); whether diseases are
assumed to be either absent or present, or modeled as progress-
ing continuously in severity; whether the effects of multiple
treatments are multiplied or their interactions modeled in a
more physiologically realistic way; how comorbidities are
handled; how the effects of timing of treatments are handled;
and so forth.
There are several things to consider in assessing the credi-
bility of the model’s design. The ﬁrst is a clear statement of the
decision problem(s) the model is intended to address. This must
be provided in sufﬁcient detail to enable the user to evaluate not
only the credibility of the design but also its relevance to the
decision.
The second is the process used to determine the design
(parameters, interactions, mathematical structure). There should
be a formal process, and it should be well described. An informal
process (i.e., mostly in the modelers’ heads), is not only more
difﬁcult to evaluate but also more subject to errors such as
omission of important aspects and/or relationships, and use of
mathematical structures that have unrecognized limitations. The
process should begin with a description of the desired qualities of
the model—what the model should be able to do. It is important
that these qualities be identiﬁed before the structure or data
sources are chosen [10]. If the mathematical structure or data
sources are chosen ﬁrst, there is a high risk that the resulting
model will be distorted to ﬁt the preselected structure or data
sources. When building models, it is always necessary to com-
promise on the ideal list of qualities because of deﬁciencies in the
available data, but it is very important to begin with a list of
qualities. This helps ensure that there is a rigorous search for the
best possible data sources and the model comes as close as
possible to having the desired qualities. The process for designing
a model should include graphical aids such as inﬂuence dia-
grams, concept maps, and ﬂow diagrams.
The third is to examine the aspects and relationships and
determine whether they are sufﬁcient to address the intended
problems. It is not necessary that the model include every
physiological variable and other factors that might possibly affect
an outcome. The issue is whether it includes the most important
determinants of the outcome. Practical questions might take the
form “Would I believe a model’s estimate of the risk of neuro-
pathy complications if the model includes ‘diabetes,’ but does not
include its duration, severity, treatment, or response to treat-
ment?” Or “Would I believe a model’s predictions of the spread of
infection in a population if it assumes the population is evenly
spread across a geographical area, and there are no areas of
crowding?” The choices made regarding what to include and how
create considerable uncertainty in the results. This structural
uncertainty is difﬁcult to address but, at a minimum, the
modelers should identify what these elements are and address
how they might affect the results [36].
The fourth is to review the strengths and limitations of the
chosen modeling technique [37–40]. It is important that the
model be designed at an appropriate level of detail to represent
the intended decision problem. All models are simpliﬁed repre-
sentations of reality, but the simpliﬁcations must not be so
severe that they cause the model to produce misleading results.It is also important that the model’s design be based on medical
science and the decision problem, rather than a prechosen
modeling technique (e.g., regression equation, state-transition
model, and event-driven simulation). All modeling techniques
are subject to some inherent assumptions. As with most aspects
of model evaluations, the importance of any particular assump-
tion will depend on the intended uses—the key is whether the
chosen technique is appropriate for the intended uses. For
example, the assumption that time jumps forward in annual
intervals will have little detrimental effect on a model’s abi-
lity to calculate annual incidence rates, but would critically affect
its ability to analyze issues such as frequency of screening, delay
in diagnosis, optimal follow-up times for monitoring cancer
posttreatment, and so forth. Several of the more common types
of modeling techniques and their strengths, assumptions, and
limitations are described in a previous series of articles [23–25].
Data
5. Are the data used in populating the model suitable for your
decision problem?
The data used to estimate equations for the model should be
suitable for the decision problem. The user can assess this by
asking whether the values used for the inputs seem reasonable.
Users with quantitative training can assess whether adequate
methods were used for point estimate and interval estimation,
such as 95% CIs, or distributions [41]; extrapolating beyond the
observed data [42]; developing the model equations; incorporat-
ing correlation among parameters [16].
Analysis
6. Were the analyses adequate to inform your decision problem?
7. Was there an adequate assessment of the effects of uncer-
tainty? The analyses performed using the model must be
adequate to inform the decision problem. Relevant factors include
the speciﬁcation of the simulated population, interventions, and
outcomes; number of simulated individuals included in the calcu-
lation (addressing stochastic uncertainty); and time horizon. Anal-
ysis of the results should also include calculating uncertainty due
to imprecision in parameter estimates [16] and structural uncer-
tainty generated by the assumptions made in the model [43]. These
uncertainty analyses are often known as “sensitivity” analyses.
Reporting
8. Was the reporting of the model adequate to inform your
decision problem?
Adequate documentation of the model and its validation must be
provided [15,44]. While inadequate documentation does not
necessarily mean that the model is inaccurate, poorly docu-
mented models should not be considered credible. Documenta-
tion should include a freely available nontechnical description of
the model that covers the type of model and intended applica-
tions; its structure, including the aspects considered and their
relationships; modeling technique; assumptions; data sources;
validation methods and results; limitations; and funding sources.
In addition, modelers should make available (under agree-
ments that protect intellectual property, if they wish) full tech-
nical documentation in sufﬁcient detail to allow for replication of
the model.
Interpretation
9. Was the interpretation of results fair and balanced?
The interpretation of the model’s results should be fair and
justiﬁed by the results. Limitations should be discussed. Results
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(e.g., clinical trials) or other models. Speciﬁc questions include
the following: Were the results consistent with previous known
information? Are the results (differences demonstrated) consid-
ered clinically meaningful? Have the implications of the valida-
tion results been adequately considered?
Conﬂict of Interest
10. Were there any potential conﬂicts of interest?
11. If there were potential conﬂicts of interest, were steps taken
to address these? Finally, the user should assess the potential
effects of any conﬂicts of interest. Speciﬁc questions include the
following: Did the authors describe how the study was funded?
Did the sponsor have a role in the design, execution, or inter-
pretation of the study? If there were potential conﬂicts of
interest, were steps taken to address these?Final Assessment
Upon completion of the questions, each of the domains is rated
by the user as a “strength,” a “weakness,” or “neutral.” On the
basis of these evaluations, the user would then rate the credi-
bility of the research study as either “sufﬁcient” or “insufﬁcient”
to inform decision making.
Some questions may be identiﬁed as a “fatal ﬂaw.” This
means that there is a signiﬁcant risk that the ﬁndings are
misleading and the decision maker should use caution in apply-
ing the results to inform decisions. The occurrence of a fatal ﬂaw
does not prevent a user from completing the questionnaire,
however. The questionnaire also does not force the user to judge
the evidence as “insufﬁcient” but the presence of a fatal ﬂaw
should raise a strong caution and should be carefully considered
when the overall body of evidence is reviewed.
Once the user has completed the questionnaire, the assess-
ments are summarized as follows:
In evaluating this study, I made the following judgments: I found the study (relevant/not relevant) for decision making because
I considered that the population/interventions/outcomes/setting
(applied/did not apply) to the decision I am informing. I found the study (credible/not credible) for decision making because:
○ There (were/were not any) fatal ﬂaws—that is, critical elements
that call into question the validity of the ﬁndings.
■ The presence of a fatal ﬂaw suggests signiﬁcant opportunities
for the ﬁndings to be misleading and misinterpreted; extreme
caution should be used in applying the ﬁndings to inform
decisions.
■ The following domains contained fatal ﬂaws:
○ There are strengths and weakness in the model:
■ The following domains were evaluated as strengths:
■ The following domains were evaluated as weaknesses:Meeting Educational Needs
Across jurisdictions, the resources and expertise available to
inform health care decision makers vary widely. While there is
broad experience in evaluating evidence from randomized con-
trolled clinical trials, there is less experience with modeling
studies. ISPOR has provided Good Research Practice recommen-
dations on modeling studies [3,10,15,16,23–25]. This question-
naire is an extension of those recommendations and serves as a
platform to assist the decision maker in understanding what a
systematic evaluation of modeling study requires. It is hoped that
this will lead to a general increase in the understanding andapplication of evidence generated by modeling studies. To that
end, we anticipate additional educational efforts and promotion
of this questionnaire and that it will be made broadly available. In
addition, an interactive Web-based tool has been developed at
https://www.healthstudyassessment.org/ to aid and facilitate
uptake and support the educational goal that the questionnaire
provides.Conclusions
The Task Force developed a consensus-based questionnaire to
help decision makers assess the relevance and credibility of
modeling studies. The questionnaire aims to provide a guide for
assessing the degree of conﬁdence that should be placed in a
modeling analysis, and increases awareness among decision
makers of the subtleties involved in evaluating these kinds of
studies. It is anticipated that user feedback will permit periodic
evaluation and modiﬁcation to the questionnaire. The goal is to
make all the questionnaires in the series as useful as possible to
the health care decision-making community.Acknowledgments
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